{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:16:28Z","timestamp":1761164188115,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.cld.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T23:58:14Z","timestamp":1627603094000},"page":"763-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Controversies in Treating Chronic Hepatitis B virus"],"prefix":"10.1016","volume":"25","author":[{"given":"Daniel Q.","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan Sen","family":"Kew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"Global hepatitis report","key":"10.1016\/j.cld.2021.06.005_bib1"},{"year":"2015","series-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","key":"10.1016\/j.cld.2021.06.005_bib2"},{"issue":"4","key":"10.1016\/j.cld.2021.06.005_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.06.005_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/2319-4170.143485","article-title":"Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients","volume":"38","author":"Liao","year":"2015","journal-title":"Biomed J"},{"issue":"4","key":"10.1016\/j.cld.2021.06.005_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcv.2010.12.008","article-title":"Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum","volume":"50","author":"Wursthorn","year":"2011","journal-title":"J\u00a0Clin Virol"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/jvi.52.2.396-402.1984","article-title":"Large surface proteins of hepatitis B virus containing the pre-s sequence","volume":"52","author":"Heermann","year":"1984","journal-title":"J Virol Nov"},{"issue":"6","key":"10.1016\/j.cld.2021.06.005_bib8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.06.005_bib9","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase","author":"Huang","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"year":"2015","series-title":"Guideline development for the prevention, care and treatment of persons with chronic hepatitis B Appendix 2: systematic review reports and evidence summaries","key":"10.1016\/j.cld.2021.06.005_bib10"},{"issue":"6","key":"10.1016\/j.cld.2021.06.005_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cld.2021.06.005_bib12","article-title":"Should treatment indications for chronic hepatitis B be expanded?","author":"Jeng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.06.005_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1478-3231.2011.02634.x","article-title":"Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma","volume":"32","author":"Chan","year":"2012","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B","volume":"34","author":"Papatheodoridis","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2021.06.005_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003265","article-title":"Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis","volume":"3","author":"Thiele","year":"2013","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.cld.2021.06.005_bib17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10620-009-0747-y","article-title":"Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis","volume":"54","author":"Tong","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.cld.2021.06.005_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"Yuen","year":"2007","journal-title":"Antivir Ther"},{"issue":"15","key":"10.1016\/j.cld.2021.06.005_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2021.06.005_bib20","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.31557\/APJCP.2019.20.8.2239","article-title":"Association between hepatitis B surface antigen levels and the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection: systematic review and meta-analysis","volume":"20","author":"Thi Vo","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2021.06.005_bib22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jix506","article-title":"Nucleos(t)ide analogue treatment for patients with hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C infection: a nationwide, multicenter, retrospective study","volume":"216","author":"Chang","year":"2017","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.cld.2021.06.005_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut May"},{"issue":"5","key":"10.1016\/j.cld.2021.06.005_bib24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation","volume":"50","author":"Choi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.06.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.cld.2021.06.005_bib29","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: benign course towards HBsAg clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2021.06.005_bib30","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/apt.14613","article-title":"Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone","volume":"47","author":"Bonacci","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2021.06.005_bib33","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2021.06.005_bib34","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP3304","article-title":"Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data","volume":"24","author":"Pavlovic","year":"2019","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.06.005_bib37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2021.06.005_bib38","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jgh.13378","article-title":"Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: a Thai nationwide cohort study","volume":"31","author":"Charatcharoenwitthaya","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.06.005_bib39","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2021.06.005_bib40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hepr.12811","article-title":"Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-\u03b1","volume":"47","author":"Caviglia","year":"2017","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.cld.2021.06.005_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.06.005_bib43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.30474","article-title":"The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.06.005_bib44","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41598-017-02010-w","article-title":"Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg <\/= 200 IU\/mL","volume":"7","author":"Yao","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.06.005_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2021.06.005_bib47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jvh.13283","article-title":"The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: a systematic review and meta-analysis","volume":"27","author":"Fonseca","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.cld.2021.06.005_bib48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/apt.16149","article-title":"Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of qHBsAg (qHBsAg)","volume":"53","author":"Lim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2021.06.005_bib49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cca.2019.10.049","article-title":"HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: \"Loss of HBsAg\" maybe not a good end-point of anti-viral therapy","volume":"501","author":"Ma","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.cld.2021.06.005_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.cld.2021.06.005_bib51","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.06.005_bib52","doi-asserted-by":"crossref","first-page":"42879","DOI":"10.1038\/srep42879","article-title":"Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B","volume":"7","author":"Peng","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.cld.2021.06.005_bib53","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","article-title":"Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"61","author":"Marcellin","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2021.06.005_bib54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/apt.14613","article-title":"Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone","volume":"47","author":"Bonacci","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2021.06.005_bib55","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/liv.12725","article-title":"On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients","volume":"35","author":"Goulis","year":"2015","journal-title":"Liver Int"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:05Z","timestamp":1761069545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1089326121000556"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.06.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in Treating Chronic Hepatitis B virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}